$IQV

Cherofsky Keriann sold $137K of IQV

Cherofsky Keriann (See Remarks) sold 558 shares of IQVIA HOLDINGS INC. (IQV) at $245.21 ($0.14M total) on 2026-07-29.

Original reporting
SEC EDGAR · Cherofsky Keriann
Published Jul 31, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
low confidence
Mentioned
$IQV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

Insider open-market sales can be interpreted as sentiment signals, but without additional company-specific information, the trading impact is typically limited.

02

Market read

A modest insider sale was disclosed via Form 4, offering limited incremental information for trading decisions.

03

What to watch

The article does not state whether the insider’s remaining holdings are part of a broader pattern, nor does it provide context on compensation, vesting, or prior sales frequency.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-31, sale dated 2026-07-29

Background

The article is a SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralLow confidence
Context

IQVIA Form 4 shows officer Cherofsky Keriann sold 558 shares at $245.21 on 2026-07-29 for about $136.8K, after which she held 2,989 shares.

Expected impact

Likely negligible near-term price impact; any effect would be limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction value (~$137K) is modest relative to IQVIA’s market scale, and the article provides no accompanying corporate event, guidance, or legal/regulatory development.

Market effects

No sector read-through is provided beyond a single insider sale at a large healthcare/clinical research services company.

None indicated.

None indicated.

Counterpoint

The sale could be driven by personal liquidity needs or tax planning rather than a bearish view, especially since the filing does not include any negative company-specific catalyst.

Key entities

  • IQVIA Holdings Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Cherofsky Keriann

    Officer who sold 558 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVMed

Stifel raises IQVIA stock price target on improving market backdrop

Stifel raised its price target for IQVIA (NYSE:IQV) to $303 from $276, citing an improving market backdrop and strong company performance. The stock is near its 52-week high and has surged 48.72% over the past six months. Multiple analysts have raised their price targets and maintained buy ratings, highlighting IQVIA's growth prospects and strong data infrastructure.

$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.